logo
Plus   Neg
Share
Email

BTG FY Product Sales At Upper End Of Its Prior Outlook - Quick Facts

BTG plc (BTG.L) issued an update for the 12 months ended 31 March 2019, revealing product sales at the top end of the Board's view. Oncology and Vascular sales are in line with the Board's projected growth range of 15-17%. Pharmaceuticals recorded double-digit growth, ahead of the company's outlook of low single digit growth. Licensing revenues are broadly flat with previous year, the Group said.

BTG plc said its Board continues to expect that the acquisition of BTG by Boston Scientific unit, which remains subject to the satisfaction or waiver of certain conditions, to close around the middle of the calendar year 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria. Cosmetics company Revlon Inc. (REV) is reportedly considering a potential sale of parts or all of its business. According to Bloomberg, Revlon has retained financial advisers from Goldman Sachs Group Inc. to explore strategic alternatives. No deal has been reached yet, but Revlon is exploring all... China's Lenovo Group Ltd. warned it may have to raise prices of its products if the U.S. moves ahead with the decision to impose additional tariffs on Chinese goods, according to a report by Reuters. The warning by Lenovo, the world's largest PC maker, comes amid the escalating trade war between the U.S. and China that has raised concerns about the global economic outlook.
Follow RTT